Mouse Anti-THC Recombinant Antibody (clone T3) (CAT#: PABL-720)

Figure 1 Binding properties of the anti-THC T3 Fab and anti-T3-THC immunocomplex-specific 104 Fab to a THC and its metabolites.

(a) Affinity of the anti-THC T3 Fab to a THC, THC-COOH, and 11-OH-THC analyzed in a competitive ELISA. Increasing concentrations of the ligands were added into THC-BSA-coated wells to obtain inhibition of the binding. Mean values of three independent measurements are shown. (b) One-step, homogeneous immunocomplexbased assay for the THC with spiked saliva samples. The Eu-labeled anti-THC T3 Fab and Alexa Fluor 647-labeled antiT3-THC 104 Fab were mixed in saliva with increasing concentrations of the ligands, and the FRET was measured after 7 min. Error bars represent the standard deviations of three parallel measurements.

Niemi, M. H., Turunen, L., Pulli, T., Nevanen, T. K., Höyhtyä, M., Söderlund, H., ... & Takkinen, K. (2010). A Structural Insight into the Molecular Recognition of a (−)-Δ9-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection. Journal of molecular biology, 400(4), 803-814.

Figure 2 Effect of THC on the expression of proteins involved in the control of the G2-M transition.

A, Western blot analysis of the indicated proteins was done at least twice. Representative luminograms. T3, 3 μmol/L THC and T5, 5 μmol/L THC. Optical density (arbitrary units, mean ± SE) of the different proteins relative to their respective time-point control incubations (set at 100). B, EVSA-T cell viability was assayed after 72 hours of incubation with 5 μmol/L THC or vehicle. Columns, mean cell viability in THC-treated cells versus their respective vehicle-treated cells (set at 100%); bars, SE. Inset, Western blot of total Cdc2 levels in EVSA-T cells (lane 1), EVSA-T cells transfected with pIRESpuro2 (lane 2), and EVSA-T cells transfected with pIRESpuro2-Cdc2 (lane 3). A and B, significant differences from the corresponding vehicle-treated cells (*, P < 0.05; **, P < 0.01) or between THC-treated cells transfected with either pIRESpuro2 or pIRESpuro2-Cdc2 (‡, P < 0.05).

Caffarel, M. M., Sarrió, D., Palacios, J., Guzmán, M., & Sánchez, C. (2006). Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer research, 66(13), 6615-6621.